MX2018014198A - Secuencias de envolturas de flavivirus variante y usos de las mismas. - Google Patents

Secuencias de envolturas de flavivirus variante y usos de las mismas.

Info

Publication number
MX2018014198A
MX2018014198A MX2018014198A MX2018014198A MX2018014198A MX 2018014198 A MX2018014198 A MX 2018014198A MX 2018014198 A MX2018014198 A MX 2018014198A MX 2018014198 A MX2018014198 A MX 2018014198A MX 2018014198 A MX2018014198 A MX 2018014198A
Authority
MX
Mexico
Prior art keywords
protein fusion
flavivirus
asn
ser
residue
Prior art date
Application number
MX2018014198A
Other languages
English (en)
Inventor
Laing Peter
Original Assignee
Excivion Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Excivion Ltd filed Critical Excivion Ltd
Publication of MX2018014198A publication Critical patent/MX2018014198A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/18—Togaviridae; Flaviviridae
    • C07K14/1816—Flaviviridae, e.g. pestivirus, mucosal disease virus, bovine viral diarrhoea virus, classical swine fever virus (hog cholera virus), border disease virus
    • C07K14/1825—Flaviviruses or Group B arboviruses, e.g. yellow fever virus, japanese encephalitis, tick-borne encephalitis, dengue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/18—Togaviridae; Flaviviridae
    • G01N2333/183—Flaviviridae, e.g. pestivirus, mucosal disease virus, bovine viral diarrhoea virus, classical swine fever virus (hog cholera virus) or border disease virus
    • G01N2333/185—Flaviviruses or Group B arboviruses, e.g. yellow fever virus, japanese encephalitis, tick-borne encephalitis, dengue
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Zoology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La invención se refiere a análogos recombinantes aislados de bucles de fusión de proteína E de flavivirus que comprenden al menos un sitio de glicosilación para un glicano ligado a N que no está presente en la secuencia de bucle de fusión de proteína E de flavivirus natural, en el que al menos un sitio 5 de glicosilación es un secuón de glicosilación ligado a N (Asn-X-Ser/Thr) y el residuo Asn (N) del secuón ocupa cualquiera de las posiciones 98-110 (DRGWGNGCGLFGK) de la secuencia de aminoácidos del bucle de fusión de la proteína E de flavivirus natural, en el que X es cualquier residuo de aminoácido, excepto prolina, y Ser/Thr denota un residuo de serina o treonina.
MX2018014198A 2016-05-20 2017-05-22 Secuencias de envolturas de flavivirus variante y usos de las mismas. MX2018014198A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB1608896.5A GB2550418A (en) 2016-05-20 2016-05-20 An improved vaccine against flaviviruses avoiding elicitation or stimulation of infection-enhancing antibodies
PCT/US2017/033882 WO2017201543A1 (en) 2016-05-20 2017-05-22 Variant flavivirus envelope sequences and uses thereof

Publications (1)

Publication Number Publication Date
MX2018014198A true MX2018014198A (es) 2019-08-21

Family

ID=56369688

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018014198A MX2018014198A (es) 2016-05-20 2017-05-22 Secuencias de envolturas de flavivirus variante y usos de las mismas.

Country Status (18)

Country Link
US (2) US11028133B2 (es)
EP (2) EP3458471B1 (es)
JP (1) JP7121396B2 (es)
KR (1) KR20190008896A (es)
CN (1) CN109415414A (es)
AU (1) AU2017268479B2 (es)
BR (1) BR112018073681A2 (es)
CA (1) CA3025076A1 (es)
DK (1) DK3458471T3 (es)
GB (2) GB2550418A (es)
HU (1) HUE049543T2 (es)
IL (1) IL263054A (es)
MX (1) MX2018014198A (es)
PE (1) PE20190130A1 (es)
PH (1) PH12018502441A1 (es)
RU (1) RU2018142835A (es)
SG (1) SG11201810157QA (es)
WO (2) WO2017201543A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2550418A (en) * 2016-05-20 2017-11-22 Laing Peter An improved vaccine against flaviviruses avoiding elicitation or stimulation of infection-enhancing antibodies
EP3621645A4 (en) * 2017-05-10 2021-01-27 University of Massachusetts BIVALENT DENGUE / HEPATITIS B VACCINES
TWI658848B (zh) * 2018-02-13 2019-05-11 國立清華大學 茲卡病毒疫苗組合物及其應用
CN109627294B (zh) * 2018-12-29 2020-10-09 四川大学 一种正确折叠的重组狂犬病毒g蛋白胞外段及其潜在应用
WO2020198865A1 (en) * 2019-04-03 2020-10-08 The University Of British Columbia Oligopeptides for quantitative viral proteomic analysis methods and uses
MX2022005498A (es) * 2019-11-07 2022-08-11 Inst Microbiology Cas Vacuna del zika/dengue y aplicación de la misma.
JP2023546048A (ja) * 2020-10-07 2023-11-01 サノフィ・パスツール 改良された診断試験
GB202019843D0 (en) 2020-12-16 2021-01-27 Coronex Ltd Lateral flow tests
WO2024081625A1 (en) * 2022-10-11 2024-04-18 University Of Maryland, Baltimore Engineered flavivirus envelope glycoprotein immunogenic compositions and methods of use

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1057534C (zh) 1993-08-17 2000-10-18 柯瑞英-艾格公司 促红细胞生成素类似物
WO2007015783A2 (en) * 2005-07-22 2007-02-08 Research Development Foundation Attenuated strains of flaviviruses , and uses thereof
US7943148B1 (en) * 2007-04-04 2011-05-17 The United States Of America As Represented By The Secretary Of The Army Amino acid sites in Flavivirus E proteins useful for development of diagnostics and vaccines
CN104428312A (zh) * 2012-04-02 2015-03-18 北卡罗来纳-查佩尔山大学 用于登革病毒表位的方法和组合物
GB201413086D0 (en) * 2014-07-23 2014-09-03 Imp Innovations Ltd And Inst Pasteur Methods
GB2550418A (en) * 2016-05-20 2017-11-22 Laing Peter An improved vaccine against flaviviruses avoiding elicitation or stimulation of infection-enhancing antibodies

Also Published As

Publication number Publication date
IL263054A (en) 2019-01-31
KR20190008896A (ko) 2019-01-25
PE20190130A1 (es) 2019-01-17
GB201719423D0 (en) 2018-01-03
US20200215180A1 (en) 2020-07-09
PH12018502441A1 (en) 2019-05-15
GB2550418A (en) 2017-11-22
RU2018142835A (ru) 2020-06-22
EP3458471A1 (en) 2019-03-27
BR112018073681A2 (pt) 2019-02-26
CA3025076A1 (en) 2017-11-23
AU2017268479A1 (en) 2018-12-06
AU2017268479B2 (en) 2021-04-01
US11028133B2 (en) 2021-06-08
WO2017201543A1 (en) 2017-11-23
US11401307B2 (en) 2022-08-02
CN109415414A (zh) 2019-03-01
GB201608896D0 (en) 2016-07-06
HUE049543T2 (hu) 2020-09-28
WO2018215495A1 (en) 2018-11-29
JP2019520058A (ja) 2019-07-18
SG11201810157QA (en) 2018-12-28
EP3458471B1 (en) 2020-03-25
JP7121396B2 (ja) 2022-08-18
DK3458471T3 (da) 2020-07-06
EP3630796A1 (en) 2020-04-08
US20190300580A1 (en) 2019-10-03

Similar Documents

Publication Publication Date Title
PH12018502441A1 (en) Variant flavivirus envelope sequences and uses thereof
EA201790934A1 (ru) ВАРИАНТЫ ИНТЕРФЕРОНА α2b
PH12018502465A1 (en) Mic-1 compounds and use thereof
EA033386B1 (ru) Рекомбинантные иммуногенные полипептиды стеблевого домена гемагглютинина вируса гриппа а и их применение
EP4223773A3 (en) Methods
ATE549028T1 (de) Stabile analoga von glp-1
PH12015502612B1 (en) Influenza virus vaccines and uses thereof
PH12019550241A1 (en) Mic-1 compounds and uses thereof
RU2017119773A (ru) Пептидные антагонисты пептидных гормонов из семейства кальцитонина (cgrp) и их применение
EA202190240A1 (ru) Варианты рекомбинантного белка
WO2017027848A8 (en) Glycosylated peptides with pseudoproline residues and having enhanced half-lives and ability to cross the blood brain barrier
PL397595A1 (pl) Przeciwnowotworowe bialko fuzyjne
CL2017003228A1 (es) Fragmentos mutantes de proteína ras
PH12017502323A1 (en) Novel xylanase
EA201792362A8 (ru) Композиции и способы для лечения целиакии спру
MX2023001595A (es) Proteinas de fusion que comprenden proteinas de leche y composiciones de las mismas.
WO2017060318A3 (en) Kaurenoic acid hydroxylases
MX2016007407A (es) Peptidos resistentes a proteasa.
MY195726A (en) Steviol Glycoside Transport
MX2019008549A (es) Anticuerpos dirigidos a los huesos.
PH12017550134A1 (en) Il-37 variants
BR112017014737A2 (pt) formulação de peptídeos inibidores de mk2
BR112018072968A2 (pt) peptídeos monolipidados resistentes às proteases
MX2018000023A (es) Particulas semejantes a virus recombinantes que utilizan la proteina gag del virus de inmunodeficiencia bovina.
WO2016089968A3 (en) Thermoreversible hydrogels from the arrested phase separation of elastin-like polypeptides